Initial Beneficial Ownership · 3
Iovance Biotherapeutics, Inc.
IOVANASDAQEQUITYCurrent
Initial Beneficial Ownership
Structured filing — 3
tm2626734-1_3seq1.xml
Filing details
- Report period
- 2026-09-30
- Issuer
- IOVANCE BIOTHERAPEUTICS, INC.
- Issuer CIK
- 0001425205
- Trading symbol
- IOVA
- No securities owned
- Checked
Reporting owner 1
- Name
- Berkowitz Noah
- Reporting owner CIK
- 0001369900
- Relationship
- Officer
- Officer title
- Chief Medical Officer
- Address
- C/O IOVANCE BIOTHERAPEUTICS, INC., 300 ROUSE BLVD., PHILADELPHIA, PA, 19112
Remarks
1. On September 30, 2026, Noah Berkowitz joined Iovance Biotherapeutics, Inc. (the "Issuer") as its Chief Medical Officer.
Signature 1
- Signed
- /s/ Noah Berkowitz
- Date
- 2026-10-02
Company context
Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit www.iovance.com.